In adults with type 2 diabetes and symptomatic peripheral artery disease, semaglutide increased the maximum walking distance on a treadmill at week 52 more than placebo.
In plain wordsIn adults with type 2 diabetes and leg artery disease, semaglutide improved treadmill walking distance after 52 weeks more than placebo.
- Peptide
- Semaglutide
- Outcome
- IncreaseRatio to baseline of maximum walking distance at week 52
- Study
n = 792
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Exercise and physical function · Cardiovascular
- Studied dose
- 1.0 mg once per week · subcutaneous · 52 weeksAs given in this study (human).
Measurements
- Estimated treatment ratio
- 1.13 ratio
- semaglutide vs placebo, week 52
Source sentences
The estimated median ratio to baseline in maximum walking distance at week 52 was significantly greater in the semaglutide group than the placebo group (1·21 [IQR 0·95-1·55] vs 1·08 [0·86-1·36]; estimated treatment ratio 1·13 [95% CI 1·06-1·21]; p=0·0004).
3 context sentences(design, population, supporting numbers)
The primary endpoint was the ratio to baseline of the maximum walking distance at week 52 measured on a constant load treadmill in the full analysis set.
Participants were aged 18 years and older, with type 2 diabetes and peripheral artery disease with intermittent claudication (Fontaine stage IIa, able to walk >200 m) and an ankle-brachial index of less than or equal to 0·90 or toe-brachial index of less than or equal to 0·70.
Participants were randomly assigned (1:1) using an interactive web response system to receive subcutaneous semaglutide 1·0 mg once per week for 52 weeks or placebo.